Literature DB >> 7643543

Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment.

S Hörkkö1, K Huttunen, Y A Kesäniemi.   

Abstract

The clearance of low-density lipoprotein (LDL) was studied in eleven patients on hemodialysis (HD) treatment and nine patients on continuous ambulatory peritoneal dialysis (CAPD) treatment and compared with the clearance of LDL in nine control subjects. The clearance rates for LDL (fractional catabolic rate, FCR) in all the uremic patients (FCR for LDL 0.305 +/- 0.075 pools/day, mean +/- SD) were significantly lower than the clearance of LDL in the control subjects (FCR for LDL 0.376 +/- 0.045 pools/day; P = 0.01). The clearance of LDL in the HD patients (FCR for LDL 0.334 +/- 0.066 pools/day) was only mildly decreased in comparison to the control subjects (P = 0.122), but the clearance of LDL in the CAPD patients was markedly decreased (FCR for LDL 0.268 +/- 0.072 pools/day) in comparison to the control subjects (P = 0.001). The FCR for LDL among all the patients was negatively related to the plasma total cholesterol (r = -0.56, P = 0.01) and LDL cholesterol concentration (r = -0.76, P = 0.0002) and LDL apolipoprotein B concentration (r = -0.48, P = 0.03). In conclusion, the clearance of LDL is decreased in uremic patients on dialysis treatment. This alteration in the LDL metabolism of the uremic patients may contribute to their accelerated atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643543     DOI: 10.1038/ki.1995.239

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  Avenues for post-translational protein modification prevention and therapy.

Authors:  Mengyao Tang; Sahir Kalim
Journal:  Mol Aspects Med       Date:  2022-02-25

Review 2.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

3.  Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.

Authors:  X Yang; H Wang; Z Zhu; A Deng
Journal:  J Tongji Med Univ       Date:  1997

4.  Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study.

Authors:  Sahir Kalim; Anders H Berg; Subbian Ananth Karumanchi; Ravi Thadhani; Andrew S Allegretti; Sagar Nigwekar; Sophia Zhao; Anand Srivastava; Dominic Raj; Rajat Deo; Anne Frydrych; Jing Chen; James Sondheimer; Tariq Shafi; Matthew Weir; James P Lash
Journal:  Nephrol Dial Transplant       Date:  2021-12-31       Impact factor: 7.186

Review 5.  Protein carbamylation in kidney disease: pathogenesis and clinical implications.

Authors:  Sahir Kalim; S Ananth Karumanchi; Ravi I Thadhani; Anders H Berg
Journal:  Am J Kidney Dis       Date:  2014-07-16       Impact factor: 8.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.